Skip to content

ALX ONCOLOGY INC

ALXO

Latest QuantConomy context for ALXO: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
20
Asset profile

ALX ONCOLOGY INC

QuantConomy has a structured record for ALXO. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
ALXO
Name
ALX ONCOLOGY INC
Coverage
3 market/data records
Sources
alphavantage alpaca fmp sec nasdaq
Latest signal rows

Recent signals for ALXO

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
corporate event
material agreement
bullish
95
Jun 26, 08:26 PM ALXO filed 8-K: Material Definitive Agreement, Termination of Material Agreement, Direct Financial Obligation - 3 material events - [very strong bullish signal]
earnings
earnings release
neutral
40
Feb 27, 12:00 AM ALXO filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-27. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
earnings
earnings release
neutral
40
May 8, 12:00 AM ALXO filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-05-08. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

Market coverage

Market Exchange Source Asset record
ALXO NASDAQ alphavantage Alx Oncology Holdings Inc
ALXO NASDAQ alpaca ALX Oncology Holdings Inc. Common Stock
ALXO NASDAQ fmp ALX Oncology Holdings Inc.

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
1
Rows
20
Date Insider Role Type Shares Price Value Filing
Jul 1, 2026 Wong Shelly SVP, FINANCE AND CAO sale 1,404 $2.04 $2,864 4 on EDGAR
Apr 16, 2026 Knight Jeff E. Chief Dev & Operating Officer grant 800,000 4 on EDGAR
Apr 16, 2026 Klencke Barbara Chief Medical Officer grant 100,000 4 on EDGAR
Mar 19, 2026 Pinto Shelly SVP, FINANCE AND CAO sale 903 $2.17 $1,960 4 on EDGAR
Mar 19, 2026 Lettmann Jason CHIEF EXECUTIVE OFFICER sale 12,311 $2.17 $26,715 4 on EDGAR
Mar 3, 2026 Klencke Barbara Chief Medical Officer grant 700,000 4 on EDGAR
Klencke Barbara Chief Medical Officer 3 on EDGAR
Feb 18, 2026 Pinto Shelly SVP, FINANCE AND CAO sale 565 $2.27 $1,283 4 on EDGAR
Feb 17, 2026 Lettmann Jason CHIEF EXECUTIVE OFFICER other 2,201 $2.27 $4,996 4 on EDGAR
Feb 2, 2026 GOODMAN COREY S Director, 10% owner purchase 3,184,713 $1.57 $4,999,999 4 on EDGAR
Jan 26, 2026 Lettmann Jason CHIEF EXECUTIVE OFFICER grant 912,000 4 on EDGAR
Jan 26, 2026 Pinto Shelly SVP, FINANCE AND CAO grant 192,000 4 on EDGAR
Jan 26, 2026 Shantharam Harish Chief Financial Officer grant 303,000 4 on EDGAR
Jan 20, 2026 Garland J. Scott Director grant 40,400 4 on EDGAR
Jan 20, 2026 Sandler Alan B. Director grant 10,100 4 on EDGAR
Jan 20, 2026 Hemrajani Rekha Director grant 40,400 4 on EDGAR
Jan 20, 2026 Curran Daniel J. Director grant 16,833 4 on EDGAR
Jan 20, 2026 Takimoto Chris H Director grant 40,400 4 on EDGAR
Jan 20, 2026 GOODMAN COREY S Director, 10% owner grant 40,400 4 on EDGAR
Jan 6, 2026 Pinto Shelly SVP, FINANCE AND CAO sale 3,925 $1.11 $4,357 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query ALXO context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access